Home > Research Areas
Cat. No. Product name CAS No.
DC2710 Abiraterone (CB-7598)

Abiraterone (CB-7598) is a potent CYP17 inhibitor with IC50 of 2 nM.

154229-19-3
DC4127 ABT-263 (Navitoclax) Featured

ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.

923564-51-6
DC9706 ABT-639 Featured

ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker. ABT-639 blocks recombinant human T-type (Cav3.2) Ca2+ channels in a voltage-dependent fashion (IC50 = 2 μM) and attenuates LVA currents in rat DRG neurons (IC50 = 8 μM).

1235560-28-7
DC1022 ABT-737 Featured

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively.

852808-04-9
DC7353 ABT-751(E 7010) Featured

ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.

141430-65-1
DC4231 Linifanib (ABT-869) Featured

ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families.

796967-16-3
DC11155 ABX-1431 Featured

ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL).

1446817-84-0
DC11183 ABX-1431 hydrochloride Featured

ABX-1431 (ABX1431) is a highly potent, selective, orally available, CNS-penetrant monoacylglycerol lipase (MGLL) with IC50 of 14 nM (hMGLL).

2043074-64-0
DC9660 Acalabrutinib(ACP196) Featured

Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK.

1420477-60-6
DC8760 Acalisib Featured

Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ with IC50 value of 12.7 nM.

870281-34-8
DC9986 Acebilustat(ZK322) Featured

Acebilustat(ZK322) is a potent and selective leukotriene A4 hydrolase inhibitor.

943764-99-6
DC10318 Acelarin Featured

Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.

840506-29-8
DC9900 Acetaminophen Featured

Acetaminophen is a COX inhibitor for COX-1 and COX-2 with IC50 of 113.7 μM and 25.8 μM, respectively.

103-90-2
DC11512 Acrizanib Featured

Acrizanib(LHA510) is a potent and selective angiogenesis inhibitor and VEGFR‑2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.

1229453-99-9
DC11439 Nemorexant Featured

ACT-541468 is a dual orexin receptor antagonist.

1505484-82-1
DC10417 Acumapimod (BCT197) Featured

Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α.

836683-15-9
DC8476 ACY-738 Featured

ACY-738 demonstrates inhibitory activity against recombinant HDAC6 with IC50 values of 1.7 nM, with respective average selectivity over class I HDACs being 100-fold.

1375465-91-0
DCAPI1273 Acyclovir (Aciclovir)

Acyclovir (Aciclovir)

59277-89-3
DC11886 Adavivint Featured

Adavivint (SM-04690, SM 04690, SM04690) is a novel small molecule Wnt pathway inhibitor with EC50 of 3 nM in vitro

1467093-03-3
DC7050 ADL5859 HCl Featured

ADL5859 agonizes δ-opioid receptor with a 1000-fold selectivity than µ- or κ-opioid receptor with Ki of 32 nM and 37 nM, respectively.ADL5859 displays weak inhibitory activity at the hERG channel with an IC50 of 78 μM. The EC50 of ADL5859 against δ opioid

850173-95-4
DC11097 ADX-102 (Reproxalap;NS-2) Featured

ADX-102 (Reproxalap, NS-2) is a novel small molecule immunomodulator that covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal, which have been shown to mediate inflammatory pain; DX-102 is a promising agent for the treatment of dry eye disease.

916056-79-6
DC5113 AEE-788 (NVP-AEE788) Featured

AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2.

497839-62-0
Page 5 / Total 59 FirstPrevNextLastGoto